Det var da en god nyhet.De ser store intekter i Sippi.Spennende og se hvordan spitten blir hvor mange % av aksjene går ut til Sippi divisjonen.

Ingerø Reiten har satt i gang prosessen med å utvikle potensialet de så i Navamedic da de tok over aksjene til Storvestre november 2018.

De andre aksjonærene kan bare lene seg tilbake og nyte reisen!

Mulig det blir en emisjon nå da?

Endelig så har det kommet inn folk i Nava med hjerne , nå blei Nava aksjonærene 100 mil rikere ,det hjelper med nye eiere noe jeg også venter på skal skje i biotec Ph ,

Forrige CEO la det gode grunnlaget som gjorde Reiten & Co interessert. Så det blir feil å si at det "Endelig så har det kommet inn folk i Nava med hjerne".
Forstår ikke helt hva du mener med det.
Ser fram til presentasjonen i morgen.

19/06-2019 16:00:06: (NAVA) Proposed demerger of Navamedic ASA with transfer to Observe Medical ASA

Reference is made to the stock exchange announcement of 14 May 2019 regarding
the proposed restructuring of Navamedic ASA (the "Company" or "NAVA" and
together with its direct and indirect subsidiaries, the "NAVA group"), whereby
the Company's Medtech division is demerged from the Company and merged into a
newly incorporated entity, Observe Medical ASA ("OM ASA" and together with its
direct and indirect subsidiaries following the completion of the demerger, the
"OM ASA group"), which will be listed on Oslo Axess upon completion of the
demerger.

The board of directors of NAVA and OM ASA today announce that they have signed a
joint demerger plan and resolved to propose to their respective general meetings
that the shareholders shall approve the demerger of NAVA, whereby all of NAVA's
shares in Observe Medical International AB are transferred to OM ASA together
with an earn-out obligation (a contingent consideration) to the sellers of
Observe Medical International AB related to the Company's acquisition of Observe
Medical International AB in 2015 (the "Contingent Consideration"), while all
other assets, rights and liabilities will remain with NAVA. The Contingent
Consideration is further described in notes 10 and 23 to NAVA's consolidated
annual financial statements for 2018. Upon completion of the demerger, Observe
Medical International AB will be a wholly owned subsidiary of OM ASA and OM ASA
will indirectly be the owner of Observe Medical International AB's direct and
indirect subsidiaries, Observe Medical Aps and Navamedic MedTec AB,
respectively.

The board of directors and management of NAVA have evaluated the most suitable
organisation of NAVA in order to facilitate further growth and enhanced values
for its shareholders. As there are few synergies between commercialising medical
technology on a global market (the Medtech division) and NAVA's core business of
growing a market access platform for pharma companies in Northern Europe, it was
concluded that a demerger would benefit both businesses. The demerger will
create a simpler and clearer corporate structure visualising the existing values
of NAVA, and is therefore expected to provide both NAVA and OM ASA with more
flexibility and a better basis to raise capital for their respective businesses.
The demerger will allow NAVA to focus on developing its core business areas
within distribution, marketing and sale of pharma and healthcare products, while
OM ASA will focus on the commercialisation of Sippi and further development of
the Medtech business. The demerger will as such facilitate further growth for
both companies.

Financial effects of the demerger

Following the entering into of the joint demerger plan, NAVA expects to present
the OM ASA group, including excess values related to the OM ASA group as
reported in the NAVA group and the Contingent Consideration, as held for
distribution and discontinued operations according to IFRS 5 Non-current Assets

Lang melding, se resten her:

http://www.navamedic.com/newsroom/2019/06/proposed-demerger-of-navamedic-asa-with-transfer-to-observe-medical-asa/

En genistrek av Gamborg.

6/28/2019 2:20:00 PM

Reference is made to Navamedic ASA's (the "Company") stock exchange announcement dated 19 June 2019 regarding the proposed demerger of the Company.

The demerger is subject to the approval by the Company's General Meeting and the board of directors has summoned to an Extraordinary General Meeting to be held at 15:00 hours (CET) on 5 August 2019 at the Company's offices in Henrik Ibsens gate 90, 3rdfloor (House of Business),0255 Oslo. Notice of the meeting has been sent to all shareholders with known address. Attached hereto is the notice of the Extraordinary General Meeting and the demerger plan. The demerger plan and other demerger documents can also be found at the Company's webpage www.navamedic.com.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 860
E-mail: kathrine@navamedic.com
Toril Ås, CFO, Navamedic
Mobile: +47 957 01 071
E-mail: toril.as@navamedic.com

Lest og liker det👍
Du får 1 OM aksje for hver Nava aksje
Og det blir hentet inn ny kapital så vi får ett nytt sterkt selskap til å drive Sippi videre.

Navamedic/Observe Medical ASA søker etter CEO i forbindelse med utfisjonering:

Chief Executive Officer (CEO)
Arbeidsgiver: Observe Medical ASA
Stillingstittel: Chief Executive Officer (CEO)
Sted: Oslo
Frist: 12.08.2019
Varighet: Fast

https://www.finn.no/job/fulltime/ad.html?finnkode=152378844&alertType=ss&WT.synd_type=agent&stored-id=28640714

Navamedic er i rute for notering av OM ASA om ca 3 måneder. EGF gav i dag sin tilslutning:

8/5/2019 4:05:22 PM
An Extraordinary General Meeting of Navamedic ASA (the "Company") was held today, on 5 August 2019, at the Company's offices in Oslo. The minutes from the Extraordinary General Meeting are attached hereto.
The general meeting adopted all the proposals on the agenda, including the approval of the joint demerger plan dated 19 June 2019 for the demerger of the Company as the transferring company with Observe Medical ASA as the acquiring company.
Subject to the satisfaction of the conditions precedent for the demerger, the demerger is expected to be completed and become effective in the end of October 2019 or the beginning of November 2019.
Upon completion of the demerger, the Company's share capital will be decreased from NOK 11,867,673 to NOK 8,782,078.02, by decreasing the nominal value of the Company's existing shares from NOK 1 to NOK 0.74. The Company's shareholders will receive newly issued shares in Observe Medical ASA as demerger consideration in the same ratio as they own shares in the Company when the demerger becomes effective (1:1). The listing of Observe Medical ASA's shares on Oslo Axess is a condition precedent for the demerger.
The Company will publish a stock exchange announcement when the demerger and the corresponding share capital decrease is registered with the Norwegian Register of Business Enterprises (Nw: Foretaksregisteret).

Men dere... Oberve Med. Er det bare Sippi det har, eller er det mer..? Har Sippi (potensielle) konkurrenter, og er utskillingen av Observe Med. en slags dekkoperasjon for bare å bli kvitt den biten..? Litt paranoid spørsmål, men det måtte visst til... En litt annen ting er at urinmåling kanskje ikke er det mest «sexye» å investere i...
🤣👍

At Sippi har stort potensiale er forsiktig sagt. Det er et patentert og gjennomprøvd system som pr. idag ikke har konkurranse fra annet enn manuell betjening utført av overarbeidede sykepleiere. Nå starter utrullingen i markedet.

"Based on a high-retention business model, Navamedic is approaching attractive markets with a unique, clinically validated
and regulatory approved product which meets a significant medical need. Navamedic’s Medtech business is targeting an
attractive NOK 4 billion global market for Sippi® and a NOK 20 billion global market for Sippbag. The board has proposed
a demerger and separate listing of the Medtech division during fourth quarter 2019."

Kan noen forklare meg. Har dette noen annen betydning for mine aksjer annet enn at de forhåpentligvis stiger?

Uopplyst: Når Navamedic utfisjonerer Observe Medical så er det satt en teoretisk verdi på det som blir igjen i Navamedic og hva Observe er verdt. Dette er opplyst i prosent 74/Navamedic og 26/Observe Medical. Hvis du tar utgangspunkt i dagens kurs så kan du teoretisk se for deg hva kursen blir på Observe Medical ved notering.

Hva markedet vil prise Navamedic til etter noteringen er det jo selvfølgelig vanskelig å vite, men det er ingen grunn til at det skal prises mye lavere en i dag.


Terms of the demerger and timetable The demerger is proposed to be carried out as a demerger by way of a transfer to an existing company ("demerger and merger" (Nw: fisjonsfusjon)) in accordance with Chapter 14 of the Norwegian Public Limited Liability Companies Act.
The boards of NAVA and OM ASA have resolved upon an exchange ratio of 74%/26%, with 74% of the business to remain in NAVA and 26% of the business being transferred to OM ASA. The exchange ratio is based on an assessment made by the boards of NAVA and OM ASA, based on a valuation carried out by an external party, and founded on principles of discounted cash flow analysis, analysis of comparable transactions and the implied trading multiples of listed comparable companies.

Her kan det leses mer om transaksjonen. En av dagene nå så kommer også prospektet som sikkert vil gi flere svar.

https://mb.cision.com/Main/17619/2844928/1065670.pdf

Rockall: Her kan du få litt mer info om caset: https://aksjenorge.no/wp-content/uploads/2019/06/9_NAVAMEDIC_040619.pdf

Observe Medical er mer en bare Sippi, de har et patentert system for å forhindre infeksjoner. Dette jobber de med å utvikle videre for nye bruksområder.
Potensialet for Sippi produktene er enormt, med et markedet som omsetter årlig for 24 milliarder kroner.
Sippi har heller ingen konkurrenter på disse produktene og de har gode marginer. Nå går de på børs for skarve 60-80 millioner.

For et år siden kom Reiten&co inn som hovedaksjonær i Navamedic. De gjør veldig få transaksjoner pr år og kjøper bare i UUU-selskaper som de videreutvikler. De bidrar med kunnskap og nettverk for å gi selskapene de investerer et springbrett til suksess. Kursen har allerede begynt å røre på seg.

Her kan du se på Reiten sine suksesshistorier: https://reitenco.com/

Søknad sendt og mottatt av OB.
https://www.oslobors.no/Oslo-Boers/Notering/Aksjer-egenkapitalbevis-og-retter-til-aksjer/Nye-aksjenoteringer/Observe-Medical-ASA

Takk takk... Jeg er interessert i dette selskapet, det er jeg. Kan være en langsiktig og god investering.

Observe Medical godkjent for notering:

Oslo Børs vedtok å ta aksjene i Observe Medical ASA opp til notering på Oslo Axess. Det forutsettes at selskapet før første noteringsdag oppfyller opptakskravene på Oslo Axess. Børsdirektøren fastsetter første noteringsdag, senest 13. desember 2019.